drugset / Trial / NCT02172274

BI 10773 Administered as Oral Solution to Healthy Male Volunteers

NCT02172274

Phase 1 Completed 8 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

Study to determine the pharmacokinetics of BI 10773 and total radioactivity including excretion mass balance, excretion pathways and metabolism following the oral administration of \[14C\] BI 10773

Timeline

Start
2008-06
Primary completion
2008-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 50 mg Oral

Indications

No indication recorded.